KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $441.5 million.

  • Vertex Pharmaceuticals' Other Accumulated Expenses rose 2346.2% to $441.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $441.5 million, marking a year-over-year increase of 2346.2%. This contributed to the annual value of $363.0 million for FY2024, which is 3114.57% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $441.5 million for Q3 2025, which was up 2346.2% from $425.4 million recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Other Accumulated Expenses peaked at $648.6 million during Q1 2024, and registered a low of $201.4 million during Q3 2021.
  • Its 5-year average for Other Accumulated Expenses is $344.6 million, with a median of $316.2 million in 2023.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Other Accumulated Expenses surged by 7204.24% in 2024 and then tumbled by 4042.55% in 2025.
  • Vertex Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $268.4 million in 2021, then grew by 16.06% to $311.5 million in 2022, then soared by 69.25% to $527.2 million in 2023, then crashed by 31.15% to $363.0 million in 2024, then grew by 21.63% to $441.5 million in 2025.
  • Its Other Accumulated Expenses stands at $441.5 million for Q3 2025, versus $425.4 million for Q2 2025 and $386.4 million for Q1 2025.